Cutler Group LP Pro Qr Therapeutics N.V. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Cutler Group LP holds 4,200 shares of PRQR stock, worth $7,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,200

Previous 4,600 8.7%

Holding current value

$7,476

Previous $9,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$1.89 - $2.85 $756 - $1,140	-400 Reduced 8.7%	4,200 $9,000
Q1 2023 May 01, 2023	BUY	$1.99 - $3.66 $199 - $366	100 Added 2.22%	4,600 $9,000
Q4 2022 Feb 07, 2023	SELL	$0.8 - $3.7 $1,040 - $4,810	-1,300 Reduced 22.41%	4,500 $16,000
Q3 2022 Oct 25, 2022	SELL	$0.74 - $0.89 $1,018 - $1,224	-1,376 Reduced 19.18%	5,800 $4,000
Q2 2022 Aug 04, 2022	SELL	$0.56 - $1.0 $4,592 - $8,200	-8,200 Reduced 53.33%	7,176 $5,000
Q1 2022 Apr 14, 2022	BUY	$0.9 - $8.39 $5,409 - $50,423	6,010 Added 64.17%	15,376 $13,000
Q4 2021 Jan 18, 2022	SELL	$6.58 - $8.44 $22,595 - $28,982	-3,434 Reduced 26.83%	9,366 $75,000
Q3 2021 Oct 26, 2021	BUY	$5.16 - $8.47 $31,476 - $51,667	6,100 Added 91.04%	12,800 $107,000
Q2 2021 Jul 19, 2021	BUY	$5.75 - $7.59 $14,375 - $18,975	2,500 Added 59.52%	6,700 $45,000
Q1 2021 Apr 26, 2021	BUY	$4.14 - $9.22 $16,145 - $35,958	3,900 Added 1300.0%	4,200 $27,000
Q3 2020 Oct 27, 2020	SELL	$4.79 - $6.3 $33,051 - $43,470	-6,900 Reduced 95.83%	300 $1,000
Q2 2020 Jul 22, 2020	BUY	$4.5 - $6.53 $15,300 - $22,202	3,400 Added 89.47%	7,200 $43,000
Q1 2020 May 07, 2020	BUY	$5.25 - $9.9 $19,950 - $37,620	3,800 New	3,800 $20,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

42.1M

Call Options Held

30.1K

Put Options Held

5.3K

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $127M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account